11-hydroxyprogesterone has been researched along with Cancer of Prostate in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Scott, EE; Swart, AC; van Rooyen, D; Yadav, R | 1 |
| du Toit, T; Gent, R; Swart, AC | 1 |
2 other study(ies) available for 11-hydroxyprogesterone and Cancer of Prostate
| Article | Year |
|---|---|
CYP17A1 exhibits 17αhydroxylase/17,20-lyase activity towards 11β-hydroxyprogesterone and 11-ketoprogesterone metabolites in the C11-oxy backdoor pathway.
Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Androgens; Cell Line, Tumor; Gonadal Steroid Hormones; HEK293 Cells; Humans; Hydroxyprogesterones; Male; Progesterone; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Testosterone | 2020 |
11α-Hydroxyprogesterone, a potent 11β-hydroxysteroid dehydrogenase inhibitor, is metabolised by steroid-5α-reductase and cytochrome P450 17α-hydroxylase/17,20-lyase to produce C11α-derivatives of 21-deoxycortisol and 11-hydroxyandrostenedione in vitro.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 11-beta-Hydroxysteroid Dehydrogenase Type 2; 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Aged; Androstenedione; Cell Line, Tumor; Cortodoxone; HEK293 Cells; Humans; Hydroxyprogesterones; Male; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase | 2019 |